⚡️ Society for Immunotherapy of Cancer - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer #BladderCancer Matt Galsky Petros Grivas Shilpa Gupta Elizabeth Plimack MD Jonathan Rosenberg MD Peter Black jitc.bmj.com/content/9/7/e0…

Is there value in continuing osimertinib beyond progression? Retrospective analysis in Lung Cancer Journal showed longer PFS with continuing TKI - but this is still an open question that will be answered with the prospective COMPEL trial. lungcancerjournal.info/article/S0169-…

The results of SONIA are out on nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! nature.com/articles/s4158…

Happy Thanksgiving with the most impressive KM curve you’ll see today. PFS for first line nivo/ipi vs chemo in MSI-H mCRC. 🛻 Truck test: <0.001 nejm.org/doi/full/10.10…

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer 2y PFS➡️72% vs 14% 💥When the right drug is given to the right patient at the right time, the survival curves can be as perfect as the one below👇 nejm.org/doi/full/10.10…

💡 Highlights from #BLADDR24: Translating Data into Practice 🚨 Moderators: Cédric Lebâcle & Fred Witjes 🔥 Practical insights into intravesical instillation for bladder cancer: OncoAlert Mirrors of Medicine Efficacy Tips: Limit voiding before therapy 🚫💧 & drink fluids after 💦. Toxicity

Outcome of pts with HCC who achieved CR to ICI-based systemic therapy HEPATOLOGY Journal doi.org/10.1097/HEP.00… 🔎🌎RWD, 3933 pts 👉1- & 3-year RFS: 78% & 55% 👉1- & 3-year OS: 98% & 86% 😅Just great to report RFS in advanced HCC w/ ICI❗️ 🧐only 4%, but we are getting there... ESMO - Eur. Oncology

Out in nature results of #SONIA trial presented at #ASCO23…very important academic effort, super congrats to #GabeSonke et al…but use of #palbociclib in most cases, superiority design and relatively short follow-up should be considered OncoAlert #bcsm nature.com/articles/d4158…

Just released the 2nd version of the ESMO - Eur. Oncology Essentials for Clinicians - Breast Cancer. Honoured to have contributed w a chapter purely focused on BC in #young women. Thanks to Matteo Lambertini, MD PhD for this opportunity and to ESMO - Eur. Oncology editorial team for this effort! OncoAlert

Series of 3 cases of #ALK NSCLC that transformed to large cell neuroendocrine carcinoma (LCNEC) after 1L TKI therapy now Clinical Lung Cancer. Interestingly, all had concurrent on target ALK mutations. Highly variable outcomes (OS 7m, 17m, 24m). clinical-lung-cancer.com/article/S1525-…

🌟 Looking ahead: Prostate Cancer (PCa) management in 2025 Moderator: Amit Bahl | Nuclear Medicine Insights by Karolien Goffin #PROSCA24 OncoAlert Mirrors of Medicine 🔹 PSMA-based Radioligand Therapy (RLT) 🧬 PSMAfore: 12.0 vs 5.6 months (PFS benefit) 🧬 SPLASH: 9.5 vs 6.0 months

In pts with #EGFR #NSCLC, what is the value of continuing osimertinib with platinum-pemetrexed after progression vs stopping osimertinib & switching to platinum pemetrexed? I’m proud to present our multi-center, retrospective, international series published in Everyday Health 🧵

It is truly an honor and joy to be featured in The ASCO Post! 🌟 Reflecting on the power of social media in oncology, the significance of global collaboration, and the invaluable lessons I gained during my time at Dana-Farber Cancer Institute has been deeply meaningful. The

Cedars-Sinai #GIpathology study characterizes the clinicopathology of metastases to the stomach & provides insight on how to differentiate between gastric mets vs. primary #gastric #adenocarcinoma pubmed.ncbi.nlm.nih.gov/39580093/ OncoAlert Human Pathology

Finals pics from #ESMOpreceptorship on #BreastCancer in 🇸🇬…thank you so much ESMO - Eur. Oncology, its super staff, our great chair Rebecca Dent, all faculty and participants for making these 2 days so engaging!!! OncoAlert Icro Meattini Kevin Punie Belinda Kiely Università di Genova Ospedale San Martino Genova

While EVP is better than platinum based chemotherapy in advanced bladder cancer, the debate whether cisplatin is much better than carbo goes on. Here we show cisplatin combines a bit better with pembro than carbo. Matt Galsky maybe winning #ESMOasia24 gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Future of ADCs in NSCLC looks more promising for EGFRm NSCLC Pooled analysis TROPION Lung01&05evaluating datopotamab deruxtecan in EGFRm. Activity promising, but ~ to platinum/Pemetrexed. Future? Osi -> Chemo -> Dato? Osi + Ct -> Dato? Lazer + Ami ->CT->Dato? #ESMOASIA24

Enjoyed discussing #glutamine & cancer with ⁦Geo Espinosa⁩ on the Dr. Geo Podcast ⁦NYU Langone Urology⁩ ⁩⁦Cancer at Cedars-Sinai⁩ ⁦Top Biomedical Science⁩ ⁦UroToday.com⁩ ⁦Cancer Links⁩ ⁦Open Oncology⁩ ⁦ONCOassist® | The go-to oncology app⁩ ⁦OncoDaily⁩ youtu.be/sVuEiq90bQU?si…

🚨Major breakthrough from #PressRelease The MARIPOSA study reports a statistically significant and clinically meaningful improvement in overall survival (OS), reshaping the treatment landscape for patients with EGFR mutant NSCLC 🚀 jnj.com/media-center/p…

#NationalMentoringMonth in January. Indeed my proudest achievement over past year was mentoring Cedars-Sinai Internal Medicine Residency #housestaff Dr. Daniel Kim & Cancer at Cedars-Sinai postdoc Dr. Hayato Muranaka to obtain their own grant funding + develop their research concepts in #Oncology OncoAlert